chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On the 24th that evening I had a slight headache. Then the next day I still had the headache which was quite strong and the following day as well. The day after I had a slight headache not as bad but still did not go away. So, the next day I felt like the symptoms I was experiencing was weird so I went to the doctors and took a rapid test which came back positive. After testing positive I ran a fever of 98 and then up to 98.5 from there. I took Tylenol for the symptoms which didn't help with the headache at all. I also had chest pain and tightness. My symptoms lasted about a week and a half (10 days or so). Most of the symptoms have subsided except the chest pain and discomfort. It has now been six weeks of the chest discomfort. These symptoms have not went away. I also want to add the I had issues with my balance. I have noticed that when I am walking, I feel like I will tip over to the side. I also have felt off balance while sitting in a chair.
reddness and swelling from their deltoid to elbow; reddness and swelling from their deltoid to elbow; This spontaneous report was received from a physician via company representative referring to a 66-year-old patient of unknown gender. The patient's pertinent medical history, concurrent conditions and concomitant medications, drug reactions and allergies were unknown. Approximately on an unknown date in October 2019 (reported as with in the past month), the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) with lot # S012246, expiration date was not reported, but upon internal validation established as 10-FEB-2021 (dosing details, anatomical location were unknown) via intramuscular route for prophylaxis. Approximately on an unknown date in 2019 (reported as after an unknown amount of time), the patient had redness (erythema) and swelling from deltoid to elbow (peripheral swelling). The patient did not seek medical attention. There was no significant disability or incapacity, hospitalization, life-threatening, cancer and overdose. The outcome of the events erythema and peripheral swelling was recovered on an unknown date in 2019. The causal relationship between the suspect therapy and the events was not provided. No product quality complaint (PQC) involved.
She had a cough during the call; headaches; fatigue; Thought she had fever but does not know if she had; difficulty breathing; dizziness; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (difficulty breathing), DIZZINESS, COUGH, HEADACHE, and FATIGUE in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 09-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Aug-2021, the patient experienced DYSPNOEA (difficulty breathing), DIZZINESS (dizziness), HEADACHE, FATIGUE, and PYREXIA. On an unknown date, the patient experienced COUGH. At the time of the report, DYSPNOEA, DIZZINESS, HEADACHE, and FATIGUE had not resolved and COUGH and PYREXIA outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications and no treatment medications were reported.  Patient query was how to treat symptoms.
hives (urticaria); This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (hives (urticaria)) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 041B21A and 041B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Jan-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced URTICARIA (hives (urticaria)). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) on 01-Jan-2022 for Hives, at an unspecified dose and frequency; HYDROCORTISONE for Hives, at an unspecified dose and frequency; PREDNISONE for Hives, at an unspecified dose and frequency; CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for Hives, at an unspecified dose and frequency and FAMOTIDINE (PEPCID [FAMOTIDINE]) for Hives, at an unspecified dose and frequency. At the time of the report, URTICARIA (hives (urticaria)) was resolving.            No concomitant medication was reported. On 03Jan2022, the patient went to the doctor as it was going out of control real quick.  Patient joined a Facebook group, called Chronic Spontaneous Urticaria after COVID19 vaccine Support Group and heard that a lot of people having a similar reaction
1 hour s/p fever malaise, HA, 2 days post macualar papular rash back trunk and posterior deltoid area x 2 weeks.  Treatment topical steriod
Fever; fatigue; Sleepy; chills; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever), FATIGUE (fatigue), SOMNOLENCE (Sleepy) and CHILLS (chills) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Feb-2021, the patient experienced PYREXIA (Fever), FATIGUE (fatigue), SOMNOLENCE (Sleepy) and CHILLS (chills). At the time of the report, PYREXIA (Fever), FATIGUE (fatigue), SOMNOLENCE (Sleepy) and CHILLS (chills) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Angioedema, UrticariaPruritus, 3 inch x 3 inch raised area. Very itchy. Ice applied. Narrative:  Advisement from EOH provider: Benedryl, ice
Edema both hands and feet, redness on chest and knees, feet, fussy attitude.
2 days swollen, painful at site. Now red and hot site; ice to site. Took apap last night and this am
Post hermetic neuralgia involving T-8 - T10 dermatomes on right in paraspinour region. No redness, vesiculation, rash, or other findings. Skin is very sensitive to touch and demonstrates burning sensation.
feels throbbing pain in her ear; feels throbbing pain in her ear; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (feels throbbing pain in her ear) and EAR PAIN (feels throbbing pain in her ear) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Mar-2021, the patient experienced PAIN (feels throbbing pain in her ear) and EAR PAIN (feels throbbing pain in her ear). At the time of the report, PAIN (feels throbbing pain in her ear) and EAR PAIN (feels throbbing pain in her ear) outcome was unknown.            No Concomitant medications was reported. Action taken with mRNA-1273 in response to the event was not applicable Treatment information was not provided
This spontaneous report as received from a physician via a company representative, refers to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On 17-AUG-2015, the patient was vaccinated with an improperly stored dose of GARDASIL 9 "0.5mL-10 Pk SD PFS-Luer-Lok" which had a lot number of L001312 and expiration date on 24-FEB-2017 (route of administration and anatomical location were not reported).  There were no concomitant medications provided. No adverse effects reported. No product quality complaint was involved. On an unspecified dates, the GARDASIL 9 had four temperature excursions as follows: one for 8 hours with a lowest recorded temperature of 29 F (-1.666666667 Celsius), one of 64 hours with a lowest recorded temperature of 31 F (-0.555555556 Celsius), one for 64 with a lowest recorded temperature of 34 F (1.111111111 Celsius), one for 72 hours with a highest recorded temperature of 33 F (0.555555556 Celsius). The vaccine status was reported as "in excursion". The vaccine status was reported as "in excursion". The vaccine storage criteria and the vaccine excursion were reported as "Refrigerator(R)". This is one of several cases from the same reporter. Additional information has been requested.
Information has been received from a lawyer regarding a case in litigation concerning an approximately 74 year old male. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 26-FEB-2009, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). On an unknown date, the patient was treated by a health care provider for the following injury resulting from his use of ZOSTAVAX: shingles. The patient claims damages as a result of: injury to himself, loss of consortium, loss of services, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
chills; possibly fever; headache; This is a spontaneous report from a contactable Other HCP (patient). This 46-year-old male patient received the second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration in the left arm at the same age on 20Apr2021 08:30 AM (lot number: ER8731) as single dose for Covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 30Mar2021 08:00 AM (lot number: ER8733) as single dose for Covid-19 immunisation. About 12 hours after the 2nd dose, the patient got the chills, and possibly fever on 20Apr2021 at 08:00 PM. The patient woke up next morning with fever and headache. No treatment was received for the adverse event. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Outcome of the events was unknown.   No follow-up attempts are needed. No further information is expected.
Vaccine was stored in refrigerator on 4-Jun-2022 and was administered on 12-Jul-2022; No adverse event; Administered the vaccine to 346 patients after the 30 day by used; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered the vaccine to 346 patients after the 30 day by used), PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 4-Jun-2022 and was administered on 12-Jul-2022) and NO ADVERSE EVENT (No adverse event) in a 75-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 058A22-2A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 12-Jul-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 12-Jul-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered the vaccine to 346 patients after the 30 day by used). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 4-Jun-2022 and was administered on 12-Jul-2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered the vaccine to 346 patients after the 30 day by used), PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 4-Jun-2022 and was administered on 12-Jul-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Administered the vaccine to 346 patients after the 30 day by used) and PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 4-Jun-2022 and was administered on 12-Jul-2022).    No concomitant medication were reported. Patient had half dose. The vial was initially stored in the refrigerator was on 4Jun2022. The vial didn't undergo any temperature excursions. No treatment information were provided.
"extreme pain", itching, and warmth in the arm that she received the vaccination; warmth in the arm that she received the vaccination.; "extreme pain", itching, and warmth in the arm that she received the vaccination; Fatigue; This spontaneous report as received from a medical assistant and refers to a 60-year-old non-pregnant female patient. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. She was allergic to metoclopramide and non-steroidal anti-inflammatory drugs (NSAIDs).   On 21-JUL-2021 in the morning, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) lot # T036820 was confirmed to be valid, expiration date 01-JUL-2022, 0.5 milliliter, intramuscularly (anatomical location was not reported) as routine immunization.    On the same date, in the evening, the patient experienced extreme pain, itching, and warmth in the arm that she received the vaccination. The patient stated that "intense pain and warmness" continued into the next day, 22-JUL-2021. She also reached out to her health care practitioner (HCP) for guidance (sought medical attention), but the reporter was unsure if any treatment was provided to the patient. The events were not cancer and the patient did not overdose. The outcome of the events was unknown.  The causality assessment between the events and the suspect vaccine was not provided. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T036820; expirationdate: 01-JUL-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent
Febrile seizure on 9/17; taken to ER; evaluation unremarkable and patient back to baseline
She had increased shortness of breath that day. She went to the emergency, and they completed a CT scan of her chest and found lots of clots. She was then hospitalized and placed on supportive care with anti-coagulants. She has had testing that shows vaccine-induced Thrombotic Thrombocytopenia. She is getting worse and worse. She has had increased weaknesses. They have given her IV ID therapy. That has not been effective. She remains hospitalized for this condition since. Her doctor referred her to the emergency room.
This case was reported by a healthcare professional and described the occurrence of injection site blisters in a 52-year-old male subject who was vaccinated wiht HAVRIX (GlaxoSmithKline). Concurrent medical conditions included penicillin allergy. Concurrent vaccination include yellow fever vaccines (non-gsk) ;manufacturer unspecified;unknown given on 16 May 2013. On 16 May 2013 the subject received 1st dose of HAVRIX (1 ml, unknown route, left arm). On 17 May 2013, 1 day after vaccination with HAVRIX, the subject experienced injection site blisters and blister on arm. The reporter stated that the subject "developed 1 blister overnight on the left arm and found them the next morning." The subject then "developed 1 blister on right arm today (day after vaccination)." The reporter was considering whether to continue the HAVRIX series. At the time of reporting, the subject had not received "medical condition" but will be "determined based on progression" of the adverse evens. The reporter stated that the HAVRIX lot number was AHAVBJ97AA which is not a valid lot number. An unsuccessful attempt was made to clarify the lot number. At the time of reporting the outcome of the events were unspecified.
swollen lymph nodes; This is a spontaneous report received from a contactable consumer (Patient). A 72-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: unknown), via an unspecified route of administration on an unknown date in Mar2021, at single dose, for covid-19 immunization. The patient medical history and concomitant medications were not reported. On an unknown date in Mar2021, the patient experienced swollen lymph nodes. The event was considered as non-serious. The outcome of the event was unknown.   Information on lot/batch number has been requested.
received the second dose of the Moderna Covid vaccine and was in the waiting area when she advised us that she was feeling lightheaded. We gave her a bottled water and moved her into the counseling area for observation. Approximately 5 minutes later passed out while seated in the chair. We immediately called 911 and rushed to ascertain her level of distress. It was determined that she was still breathing but she was unresponsive. While attempting to bring her to she began to vomit a small amount of material at which time I moved her forward to prevent aspiration. Shortly thereafter regained consciousness. Her breathing returned to normal and we advised her that she had passed out momentarily and she should relax and breathe slowly while waiting on the paramedics to arrive. I used a store monitor to get her blood pressure (159/97) and pulse (79). I asked if she had diabetes or blood sugar issues and she responded no. The paramedics arrived shortly thereafter and again took her vitals. Everything was within normal range but they advised her she should ride with them to the hospital for monitoring. refused and was escorted by the paramedics to her car. Later in the evening I called to make sure everything was still ok. She responded that after she got home she rested and had a small meal and ever since she has been perfectly fine.
redness in her arm; feverish; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (redness in her arm) and PYREXIA (feverish) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (redness in her arm) and PYREXIA (feverish). At the time of the report, VACCINATION SITE ERYTHEMA (redness in her arm) and PYREXIA (feverish) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Treatment information was not provided.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Highly irregular period, even 6 months after. Very heavy period then none. Fibrous/lumpy breasts, especially immediate before menstruation
This spontaneous report as received from a healthcare worker (also reported as medical assistant) refers to a patient of unknown age. The patient's pertinent medical history, current conditions and concomitant medications were not reported. No previous drug reactions or allergies were reported. On an unknown date the patient was vaccinated with one dose of improperly stored ZOSTAVAX 9400 PFU (dosing details were not reported) (lot # M010472, expiry date 01-JUN-2017) which was stored at a temperature of -6.6 degree centigrade for 1 hour and 32 minutes, previous excursion of a max of -6.6 degree centigrade for 8 hours and 51 minutes and a max of -9.5 degree centigrade for 23 hours and 55 minutes. Data logger was reported as no (frig tag 2 in use). No adverse effects were reported. There was no product quality complaint involved. Additional information has been requested.
No additional AE reported; ROTATEQ was administered after a temperature excursion to a patient; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies, drug reactions, allergies or medical history provided.  On 06-SEP-2022, the patient was administered a dose of improperly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, once, lot # W002562 with expiration date 12-OCT-2023, administered orally for prophylaxis (exact dose was not provided) (product storage error). The vaccine was improperly stored in the temperature of 10.1 degrees Celsius (C) for 54 minutes. It was unknown if data logger was used to capture the temperature excursion. There was no previous temperature excursion. No additional adverse event was reported (no adverse event).
1ml of COVID vaccine given instead of 0.5ml on 04/19/2021. Pt called today 04/20/2021 and stated that she was having some abdominal pain, fever up to 102, achy, and some chest pain. Called pharmacist and spoke with her of symptoms she told me to  notified patient since she was experiencing chest pain to go to the emergency room. Patient voiced understanding and stated that her husband was going with her and they were going to the ER then.
4 days after vaccine patient developed fever, nausea, vomiting, fatigue. He went to ER, was placed in ICU with concern for MI! Cath of heart was normal. Viral myocarditis was suspected. He was treated with IV antibiotics, d/ced after hospital d/c.
After the second shot, sometime in mid February, the client started noticing his eyes being itchy. His tears started feeling like acid, and will leave a rash where they have been. Client is having a rash on the right side of his head, and on the backs of both of his hands. He went to his PCP who advised to take benadryl daily. Client reports the symptoms are ongoing and have not resolved.
Has not had the 2nd dose because of the "Covid pandemic"; This case was reported by a consumer and described the occurrence of social problem in a 64-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of erythema (received 1st dose around January 2020, for tolerance refer case US2021093364).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced social problem. On an unknown date, the outcome of the social problem was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, due to covid-19 pandemic. The patient did not have the virus but did not get appointment for 2nd dose of Shingrix. The patient asked if still he could get the 2nd dose. No all information was available. This case has been linked to US2021093365 and US2021AMR094049, reported by same reporter for his wife.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021093364:Same reporter. US-GLAXOSMITHKLINE-US2021093365:Same reporter. Wife's case. 1st dose. US-GLAXOSMITHKLINE-US2021AMR094049:Same reporter. Wife's case. 2nd dose.